

Adjuvant Mistel-Therapie

Bei einem intakten Immunsystem kann die Misteltherapie Immunsystem überfordern und dabei sogar Tumor-Toleranz erzeugen.

In an intact immune system mistletoe therapy can overwhelm the immune system and thereby generate even tumor tolerance.

Die Misteltherapie ist deshalb nur bei einem geschwächten Immunsystem und bei zugleich niedrigen Tumortoleranz-Markern gerechtfertigt.

Mistletoe therapy is justified only in an immunocompromised patient with simultaneously low tumor tolerance markers.

- ➔ Immunität, Immunity http://www.erlebnishaft.de/danger_model.pdf
- ➔ Selbstorganisation http://www.erlebnishaft.de/selbst_muster_nano.pdf
- ➔ Krebs Stammzell Therapie <http://www.xerlebnishaft.de/krebsstammzelltherapie.pdf>

Douwes FR, Wolfrum DI, Migeod F (1986) [Results of a prospective randomized study: chemotherapy versus chemotherapy plus "biological response modifier" in metastasizing colorectal carcinoma]. Dtsch Z Onkol 18 (6), 155-64.

Gutsch J, Berger H, Scholz G, et al. (1988) [Prospective study in radically operated breast cancer with polychemotherapy, Helixor® and untreated controls]. Dtsch Z Onkol 21, 94-101.

Bradley GW, Clover A (1989) Apparent response of small cell lung cancer to an extract of mistletoe and homoeopathic treatment. Thorax 44 (12), 1047-8. [\[PUBMED Abstract\]](#)

Dold U, Edler L, Mäurer HCh, et al. (1991) eds.: [Adjuvant Cancer Therapy in Advanced Non-Small Cell Bronchial Cancer: Multicentric Controlled Studies To Test the Efficacy of Iscador and Polyerga]. Stuttgart, Germany: Georg Thieme Verlag.

Salzer G, Danmayr E, Wutzholfer F, et al. (1991) [Adjuvant Iscador® treatment of non-small cell bronchial carcinoma. Results of a randomized study]. Dtsch Z Onkol 23 (4), 93-8.

(1994) **Patentanmeldung**. New mistletoe lectin - with immunomodulatory activity, useful for cancer adjuvant therapy DE 4221836 A1 <http://www.google.com/patents/DE4221836A1?cl=en> 23. März 1995
8131Rejection

Lenartz D, Stoffel B, Menzel J, et al. (1996) Immunoprotective activity of the galactoside-specific lectin from mistletoe after tumor destructive therapy in glioma patients. Anticancer Res 16 (6B), 3799-802. [\[PUBMED Abstract\]](#)

Schaefermeyer G, Schaefermeyer H (1998) Treatment of pancreatic cancer with Viscum album (Iscador): a retrospective study of 292 patients 1986-1996. Complement Ther Med 6 (4), 172-7.

Heiny BM, Albrecht V, Beuth J (1998) Stabilization of **quality of life** with mistletoe lectin-1-standardized extract in advanced colorectal carcinoma. Onkologie 4 (Suppl 1), 35-9.

Sauer H (1998) Quality of life stabilization with mistletoe-1-standardized extract in advanced colorectal carcinoma [Letter]. Onkologie 4, 1180.

Lenartz D, Dott U, Menzel J, et al. (2000) Survival of glioma patients after complementary treatment with galactoside-specific lectin from mistletoe. Anticancer Res 20 (3B), 2073-6 [\[PUBMED Abstract\]](#)

Wetzel D, Schäfer M (2000) Results of a randomised placebo-controlled multicentre study with PS76A2 (standardised mistletoe preparation) in patients with breast cancer receiving adjuvant chemotherapy. [Abstract] Phytomedicine 7 (Suppl 2), A-SL-66.

Steuer-Vogt MK, Bonkowsky V, Ambrosch P, et al. (2001) The effect of an adjuvant mistletoe treatment programme in resected head and neck cancer patients: a randomised controlled clinical trial. *Eur J Cancer* 37 (1), 23-31. [\[PUBMED Abstract\]](#)

Grossarth-Maticek R, Kiene H, Baumgartner SM, et al. (2001) Use of Iscador, an extract of European mistletoe (*Viscum album*), in cancer treatment: prospective nonrandomized and randomized matched-pair studies nested within a cohort study. *Altern Ther Health Med* 7 (3), 57-66, 68-72, 74-6 passim. [\[PUBMED Abstract\]](#)

Goebell PJ, Otto T, Suhr J, et al. (2002) Evaluation of an unconventional treatment modality with mistletoe lectin to prevent recurrence of superficial bladder cancer: a randomized phase II trial. *J Urol* 168 (1), 72-5. [\[PUBMED Abstract\]](#)

Viscum album. (2002) In: *Homoeopathic Pharmacopoeia Convention of the United States: Homoeopathic Pharmacopoeia of the United States*. Washington, DC, Monograph 9444 Visc. Stauder H, Kreuser ED (2002) Mistletoe extracts standardised in terms of mistletoe lectins (ML I) in oncology: current state of clinical research. *Onkologie* 25 (4), 374-80. [\[PUBMED Abstract\]](#)

Kienle GS, Berrino F, Büssing A, et al. (2003) Mistletoe in cancer - a systematic review on controlled clinical trials. *Eur J Med Res* 8 (3): 109-19. [\[PUBMED Abstract\]](#)

Ernst E, Schmidt K, Steuer-Vogt MK (2003) Mistletoe for cancer? A systematic review of randomised clinical trials. *Int J Cancer* 107 (2), 262-7. [\[PUBMED Abstract\]](#)

Cazacu M, Oniu T, Lungoci C, et al. (2003) The influence of isorel on the advanced colorectal cancer. *Cancer Biother Radiopharm* 18 (1), 27-34. [\[PUBMED Abstract\]](#)

Ernst E., Schmidt K, Steuer-Vogt MK (2003): Mistletoe for Cancer? A systematic review of randomised clinical trials. *Int. J. Cancer* 1,107, 262-267. DOI: 10.1002/ijc.11386

G. S. Kienle, H. Keine (2003) *Die Mistel in der Onkologie. Fakten und konzeptionelle Grundlagen*. Schattauer, [ISBN 3-7945-2282-6](#).

Schöffski P, Riggert S, Fumoleau P, et al. (2004) Phase I trial of intravenous aviscumine (rViscumin) in patients with solid tumors: a study of the European Organization for Research and Treatment of Cancer New Drug Development Group. *Ann Oncol* 15 (12), 1816-24. [\[PUBMED Abstract\]](#)

Bock PR, Friedel WE, Hanisch J, et al. (2004) Retrolective, comparative, epidemiological cohort study with parallel groups design for evaluation of efficacy and safety of drugs with "well-established use". *Forsch Komplementarmed Klass Naturheilkd* 11 (Suppl 1), 23-9. [\[PUBMED Abstract\]](#)

Bock PR, Friedel WE, Hanisch J, et al. (2004) [Efficacy and safety of long-term complementary treatment with standardized European mistletoe extract (*Viscum album* L.) in addition to the conventional adjuvant oncologic therapy in patients with primary non-metastasized mammary carcinoma. Results of a multi-center, comparative, epidemiological cohort study in Germany and Switzerland] *Arzneimittelforschung* 54 (8), 456-66. [\[PUBMED Abstract\]](#)

Piao BK, Wang YX, Xie GR, et al. (2004) Impact of complementary mistletoe extract treatment on quality of life in breast, ovarian and non-small cell lung cancer patients. A prospective randomized controlled clinical trial. *Anticancer Res* 24 (1), 303-9. [\[PUBMED Abstract\]](#)

Kleeberg UR, Suci S, Böcker EB, et al. (2004) Final results of the EORTC 18871/DKG 80-1 randomised phase III trial. rIFN-alpha2b versus rIFN-gamma versus ISCADOR M versus observation after surgery in melanoma patients with either high-risk primary (thickness >3 mm) or regional lymph node metastasis. *Eur J Cancer* 40 (3), 390-402. [\[PUBMED Abstract\]](#)

Bar-Sela G, Haim N (2004) Abnoba-viscum (mistletoe extract) in metastatic colorectal carcinoma resistant to 5-fluorouracil and leucovorin-based chemotherapy. *Med Oncol* 21 (3), 251-4. [\[PUBMED Abstract\]](#)

Augustin M, Bock PR, Hanisch J, et al. (2005) Safety and efficacy of the long-term adjuvant treatment of primary intermediate- to high-risk malignant melanoma (UICC/AJCC stage II and III) with a standardized fermented European mistletoe (*Viscum album* L.) extract. Results from a multicenter, comparative, epidemiological cohort study in Germany and Switzerland. *Arzneimittelforschung* 55 (1), 38-49. [\[PUBMED Abstract\]](#)

Auerbach L, Dostal V, Václavík-Fleck I, et al. (2005) **Signifikant höherer Anteil aktivierter NK-Zellen durch additive Misteltherapie bei chemotherapierten Mamma-Ca-Patientinnen** in einer prospektiven randomisierten doppelblinden Studie. In: Scheer R, Bauer R, Becker H, et al.: Fortschritte in der Misteltherapie. Aktueller Stand der Forschung und klinischen Anwendung. Essen, Germany: KCV-Verlag, 543-54.

Matthes HF, Schad F, Buchwald D, et al. (2005) Endoscopic ultrasound-guided fine-needle Injection of *Viscum album* L. (mistletoe; Helixor M) in the therapy of primary inoperable pancreas cancer: a pilot study. [Abstract] *Gastroenterology* 128 (Suppl 2): A-T988, A433-A434.

Enesel MB, Acalovschi I, Grosu V, et al. (2005) Perioperative application of the *Viscum album* extract Isorel in digestive tract cancer patients. *Anticancer Res* 25 (6C), 4583-90. [\[PUBMED Abstract\]](#)

Grossarth-Maticek R, Ziegler R (2006) Prospective controlled cohort studies on long-term therapy of breast cancer patients with a mistletoe preparation (Iscador). *Forsch Komplementmed* 13 (5), 285-92. [\[PUBMED Abstract\]](#)

Bar-Sela G, Goldberg H, Beck D, et al. (2006) Reducing malignant ascites accumulation by repeated intraperitoneal administrations of a *Viscum album* extract. *Anticancer Res* 26 (1B), 709-13. [\[PUBMED Abstract\]](#)

Lange-Lindbergh AM, Velasco-Garrido M, Busse R (2006) **Misteltherapie als begleitende Behandlung zur Reduktion der Toxizität der Chemotherapie maligner Erkrankungen**. HTA-Bericht 44, im Auftrag der Deutschen Agentur für HTA/DIMDI und des Bundesministeriums für Gesundheit, zitiert nach www.dimdi.de

Grossarth-Maticek R, Ziegler R (2007) Prospective controlled cohort studies on long-term therapy of ovarian cancer patients with mistletoe (*Viscum album* L.) extracts iscador. *Arzneimittelforschung* 57 (10), 665-78. [\[PUBMED Abstract\]](#)

Kienle GS, Kiene H (2007) Complementary cancer therapy: a systematic review of prospective clinical trials on anthroposophic mistletoe extracts. *Eur J Med Res* 12 (3), 103-19. [\[PUBMED Abstract\]](#)

Grossarth-Maticek R, Ziegler R (2007) Prospective controlled cohort studies on long-term therapy of cervical cancer patients with a mistletoe preparation (Iscador). *Forsch Komplementmed* 14 (3), 140-7. [\[PUBMED Abstract\]](#)

Grossarth-Maticek R, Ziegler R (2008) Randomized and non-randomized prospective controlled cohort studies in matched pair design for the long-term therapy of corpus uteri cancer patients with a mistletoe preparation (Iscador). *Eur J Med Res* 13 (3), 107-20 [\[PUBMED Abstract\]](#)

Horneber MA, Bueschel G, Huber R, et al. (2008) Mistletoe therapy in oncology. *Cochrane Database Syst Rev* (2), CD003297. [\[PUBMED Abstract\]](#)

Beuth J, Schneider B, Schierholz JM (2008) Impact of complementary treatment of breast cancer patients with standardized mistletoe extract during aftercare: a controlled multicenter comparative epidemiological cohort study. *Anticancer Res* 28 (1B), 523-7. [\[PUBMED Abstract\]](#)

Horneber M, Büschel G, Huber R, Linde K, Rostock M (2008): Mistletoe therapy in oncology. *Cochrane Database of Systematic Reviews* 2008, Issue 2. Art. No.: CD003297. DOI: 10.1002/14651858.CD003297.pub2. Dieser Review wurde 2010 auch online verfügbar gemacht, unter <http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD003297.pub2/abstract>.

Kienle GS, Glockmann A, Schink M, et al. (2009) *Viscum album* L. extracts in breast and gynaecological cancers: a systematic review of clinical and preclinical research. *J Exp Clin Cancer Res* 28, 79. [\[PUBMED Abstract\]](#)

Friedel WE, Matthes H, Bock PR, et al. (2009) Systematic evaluation of the clinical effects of supportive mistletoe treatment within chemo- and/or radiotherapy protocols and long-term mistletoe application in nonmetastatic colorectal carcinoma: multicenter, controlled, observational cohort study. *J Soc Integr Oncol* 7 (4), 137-45. [\[PUBMED Abstract\]](#)

Tröger W, Jezdić S, Ždrale Z, et al. (2009) **Quality of life** and neutropenia in patients with early stage breast cancer: a randomized pilot study comparing additional treatment with mistletoe extract to chemotherapy alone. *Breast Cancer: Basic and Clinical Research* 3, 35-45.

Kienle GS, Kiene H (2010) Review article: Influence of *Viscum album* L (European mistletoe) extracts on **quality of life** in cancer patients: a systematic review of controlled clinical studies. *Integr Cancer Ther* 9 (2), 142-57. [\[PUBMED Abstract\]](#)

Kim KC, Yook JH, Eisenbraun J, et al. (2012) **Quality of life**, immunomodulation and safety of adjuvant mistletoe treatment in patients with gastric carcinoma - a randomized, controlled pilot study. *BMC Complement Altern Med* 12, 172. [\[PUBMED Abstract\]](#)

Ostermann T, Büssing A (2012) Retrospective Studies on the Survival of Cancer Patients Treated With Mistletoe Extracts: A Meta-analysis. *EXPLORE*. 8(5), 277–281. DOI: 10.1016/j.explore.2012.06.005

Bar-Sela G, Wollner M, Hammer L, et al. (2013) Mistletoe as complementary treatment in patients with advanced non-small-cell lung cancer treated with carboplatin-based combinations: a randomised phase II study. *Eur J Cancer* 49 (5), 1058-64. [\[PUBMED Abstract\]](#)

Mansky PJ, Wallerstedt DB, Sannes TS, et al. (2013) NCCAM/NCI Phase 1 Study of Mistletoe Extract and Gemcitabine in Patients with Advanced Solid Tumors. *Evid Based Complement Alternat Med* 2013: 964592. [\[PUBMED Abstract\]](#)

Lordick F (2014) Misteltherapie bei Krebs: Hoffnungsträger oder Auslaufmodell? [Mistletoe treatment for cancer—promising or passé?](#) *Dtsch Arztebl Int* 111(29-30), 491-2; DOI: 10.3238/arztebl.2014.0491
<http://www.aerzteblatt.de/archiv/161079/Misteltherapie-bei-Krebs-Hoffnungstraeger-oder-Auslaufmodell>

National Cancer Institute. (2014) Mistletoe Extracts (PDQ®). Human/Clinical Studies
<http://www.cancer.gov/cancertopics/pdq/cam/mistletoe/HealthProfessional/page5>

DKFZ Heidelberg (2014) Misteltherapie bei Krebs.
<http://www.krebsinformationsdienst.de/behandlung/mistel.php>

[Bernt - Dieter Huismans](#), 2014. Letzte Revision Februar 2017 www.Huismans.click



Back to top: <http://www.xerlebnishaft.de/misteltherapie.pdf>